Cargando…
Physiologically‐based pharmacokinetic modeling to support bioequivalence and approval of generic products: A case for diclofenac sodium topical gel, 1%
Establishing bioequivalence (BE) for dermatological drug products by conducting comparative clinical end point studies can be costly and the studies may not be sufficiently sensitive to detect certain formulation differences. Quantitative methods and modeling, such as physiologically‐based pharmacok...
Autores principales: | Tsakalozou, Eleftheria, Babiskin, Andrew, Zhao, Liang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8129718/ https://www.ncbi.nlm.nih.gov/pubmed/33547863 http://dx.doi.org/10.1002/psp4.12600 |
Ejemplares similares
-
Regulatory utility of mechanistic modeling to support alternative bioequivalence approaches: A workshop overview
por: Babiskin, Andrew, et al.
Publicado: (2023) -
Darier’s disease: treatment with topical sodium diclofenac 3% gel()
por: Campos, Marcella Oliveira Menezes Quitete de, et al.
Publicado: (2023) -
Bioequivalent pharmacokinetics for generic and originator hepatitis C direct-acting antivirals
por: Hill, Andrew, et al.
Publicado: (2018) -
Tolerability of diclofenac sodium 1% gel with concomitant medications known to interact with diclofenac
por: Peniston, John H, et al.
Publicado: (2013) -
Long-term tolerability of topical diclofenac sodium 1% gel for osteoarthritis in seniors and patients with comorbidities
por: Peniston, John H, et al.
Publicado: (2012)